Rafferty Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.18M | Sell |
126,045
-45,496
| -27% | -$426K | ﹤0.01% | 732 |
|
|
2025
Q1 | $2.11M | Sell |
171,541
-6,624
| -4% | -$81.4K | 0.01% | 568 |
|
|
2024
Q4 | $2.36M | Buy |
178,165
+6,643
| +4% | +$87.8K | 0.01% | 599 |
|
|
2024
Q3 | $3.3M | Sell |
171,522
-6,398
| -4% | -$123K | 0.01% | 511 |
|
|
2024
Q2 | $3.65M | Sell |
177,920
-195,318
| -52% | -$4.01M | 0.01% | 483 |
|
|
2024
Q1 | $8.88M | Sell |
373,238
-30,143
| -7% | -$717K | 0.03% | 310 |
|
|
2023
Q4 | $8.72M | Buy |
403,381
+119,257
| +42% | +$2.58M | 0.04% | 316 |
|
|
2023
Q3 | $4.13M | Sell |
284,124
-51,223
| -15% | -$744K | 0.02% | 435 |
|
|
2023
Q2 | $7.02M | Buy |
335,347
+52,464
| +19% | +$1.1M | 0.04% | 340 |
|
|
2023
Q1 | $5.97M | Buy |
282,883
+18,121
| +7% | +$383K | 0.04% | 342 |
|
|
2022
Q4 | $6.74M | Buy |
264,762
+118,380
| +81% | +$3.01M | 0.06% | 310 |
|
|
2022
Q3 | $3.52M | Buy |
146,382
+68,478
| +88% | +$1.65M | 0.04% | 390 |
|
|
2022
Q2 | $1.5M | Sell |
77,904
-52,575
| -40% | -$1.01M | 0.01% | 539 |
|
|
2022
Q1 | $2.27M | Sell |
130,479
-27,353
| -17% | -$475K | 0.01% | 567 |
|
|
2021
Q4 | $3.46M | Buy |
157,832
+84,100
| +114% | +$1.84M | 0.02% | 506 |
|
|
2021
Q3 | $1.41M | Sell |
73,732
-64,440
| -47% | -$1.23M | 0.01% | 729 |
|
|
2021
Q2 | $2.37M | Sell |
138,172
-7,269
| -5% | -$125K | 0.01% | 632 |
|
|
2021
Q1 | $3.25M | Buy |
145,441
+127,618
| +716% | +$2.85M | 0.02% | 434 |
|
|
2020
Q4 | $396K | Sell |
17,823
-8,573
| -32% | -$190K | ﹤0.01% | 738 |
|
|
2020
Q3 | $390K | Buy |
+26,396
| New | +$390K | ﹤0.01% | 745 |
|